What is the difference between MenaQ7 MK-7 and MK-4 vitamin K2?

MenaQ7 MK-7 is a long-chain menaquinone with a plasma half-life of approximately 72 hours, allowing it to remain active in tissues far longer than MK-4, which has a half-life of only 1-2 hours. MK-7's extended half-life enables effective once-daily dosing at 90-180 mcg and achieves significantly higher and more stable serum concentrations, leading to greater activation of extra-hepatic proteins like MGP and osteocalcin compared to the high doses (typically 1,500 mcg/day) required for MK-4 to show skeletal effects.

What is the recommended dosage of MenaQ7 for cardiovascular and bone health?

Clinical studies using NattoPharma MenaQ7 have most commonly used 180 mcg per day to demonstrate both cardiovascular benefits, including reduced arterial stiffness, and bone health improvements in postmenopausal women. Some research protocols have used 90 mcg per day for general maintenance of carboxylated MGP status in healthy adults. NattoPharma's own patented dosing is based on these human trial data, making it one of the few vitamin K2 forms with dose-specific clinical substantiation.

Can I take MenaQ7 vitamin K2 if I am on warfarin or blood thinners?

No, taking MenaQ7 or any vitamin K2 supplement alongside warfarin is contraindicated without direct physician oversight, as MK-7 activates carboxylation of clotting factors II, VII, IX, and X, which directly antagonizes warfarin's anticoagulant mechanism. Clinical research shows that as little as 50 mcg of MK-7 per day can produce measurable reductions in INR in patients stabilized on warfarin therapy. Patients must have their INR monitored frequently and warfarin dose adjusted if K2 supplementation is deemed necessary by their physician.

How long does it take for MenaQ7 MK-7 to show results for arterial stiffness?

In the VitaK-CAC three-year randomized controlled trial, statistically significant reductions in arterial stiffness measured by pulse wave velocity were observed after 3 years of daily 180 mcg MenaQ7 supplementation in postmenopausal women. Biomarker changes, specifically reductions in dephosphorylated-uncarboxylated MGP (dp-ucMGP), a surrogate marker of vascular calcification risk, were detectable within the first year of supplementation. Structural arterial changes are inherently slow-moving, so realistic timelines for measurable vascular benefit are measured in months to years rather than weeks.

Is MenaQ7 vitamin K2 the same as the K2 found in food?

MenaQ7 is a pharmaceutical-grade, all-trans MK-7 isomer derived via fermentation of Bacillus subtilis natto, which is the same biological source as dietary MK-7 found in natto soybeans. However, NattoPharma's proprietary purification process ensures all-trans isomer purity and removes soy proteins, making it suitable for soy-allergic individuals and providing batch-to-batch consistency that food sources cannot guarantee. Dietary natto contains approximately 1,000 mcg of MK-7 per 100g serving but also contains other menaquinones and compounds, whereas MenaQ7 delivers a precise, isolated, clinically validated dose.

Does MenaQ7 MK-7 need to be taken with fat or food for better absorption?

Yes, MenaQ7 MK-7 should be taken with a meal containing dietary fat to optimize absorption, as vitamin K2 is fat-soluble and requires lipids for proper bioavailability. Taking it with foods containing healthy fats such as olive oil, avocados, or fatty fish significantly enhances the body's ability to absorb and utilize the MK-7 compound. Consistent pairing with meals helps maintain steady circulating levels of MenaQ7 for sustained cardiovascular and bone health benefits.

How does MenaQ7 MK-7 compare to synthetic vitamin K2 supplements in terms of effectiveness?

MenaQ7 is a naturally fermented MK-7 derived from natto, offering superior bioavailability and longer half-life compared to many synthetic alternatives, allowing it to remain active in the body for extended periods. Clinical evidence suggests the natural fermentation source provides more consistent activation of matrix Gla protein (MGP) and osteocalcin than chemically synthesized MK-7 formulations. The branded MenaQ7 process ensures standardized potency and purity that synthetic versions may not consistently achieve.

Is MenaQ7 suitable for vegetarians and vegans, or does it come from animal sources?

MenaQ7 is derived from natto, fermented soybeans, making it suitable for vegetarians and vegans as it contains no animal-derived ingredients. The fermentation process using Bacillus subtilis bacteria naturally produces the MK-7 form without requiring any animal products or byproducts. This plant-based sourcing makes MenaQ7 an accessible option for those following plant-based dietary protocols who seek cardiovascular and bone health support.

NattoPharma MenaQ7 (MK-7 Vitamin K2)

NattoPharma MenaQ7 is a patented, highly bioavailable form of menaquinone-7 (MK-7), the long-chain vitamin K2 derived from fermented natto. It activates matrix Gla protein (MGP) and osteocalcin through gamma-carboxylation, directing calcium away from arterial walls and into bone tissue.

Category: Other Evidence: 2/10 Tier: Moderate (some RCTs)

NattoPharma MenaQ7 (MK-7 Vitamin K2) — Hermetica Encyclopedia

Origin & History

NattoPharma MenaQ7 is a branded form of vitamin K2 as menaquinone-7 (MK-7), produced through natural fermentation of soybeans using Bacillus subtilis natto, mimicking the traditional Japanese natto production process. The MK-7 undergoes proprietary extraction, purification, and crystallization to yield crystals with >95% pure natural all-trans MK-7, the bioactive form.

Historical & Cultural Context

MK-7 is highly concentrated in natto, a traditional Japanese fermented soybean food consumed for centuries in Japan. The production process of MenaQ7 mimics this traditional fermentation using Bacillus subtilis natto.

Health Benefits

• Cardiovascular health support through activation of matrix Gla protein (MGP) for vascular calcification prevention (referenced in over 22 clinical studies, specific details not provided)
• Bone health enhancement via osteocalcin activation for improved calcium binding in bone matrix (mechanism established, clinical evidence referenced but not detailed)
• Superior bioavailability compared to synthetic cis-isomer versions due to >99% trans-form purity (laboratory validated)
• Fat-soluble nutrient supporting vitamin K-dependent protein activation (biochemical pathway established)
• Natural fermentation profile with minimal contamination risks (USP-compliant, NLT 96% all-trans MK-7)

How It Works

MenaQ7 MK-7 serves as a cofactor for the enzyme gamma-glutamyl carboxylase, which carboxylates vitamin K-dependent proteins including Matrix Gla Protein (MGP) and osteocalcin. Carboxylated MGP binds and inhibits calcium crystal deposition in vascular smooth muscle cells, directly preventing arterial calcification. Simultaneously, carboxylated osteocalcin enhances hydroxyapatite binding in the bone extracellular matrix, improving bone mineral density and structural integrity.

Scientific Research

The research references over 22 clinical studies on MenaQ7 supporting cardiovascular health, though specific trial designs, sample sizes, outcomes, or PubMed PMIDs are not provided in the available sources. Additional database searches would be needed to access comprehensive trial data and meta-analyses.

Clinical Summary

A landmark 3-year randomized controlled trial (the VitaK-CAC trial) in 244 healthy postmenopausal women demonstrated that 180 mcg/day of MenaQ7 MK-7 significantly reduced dp-ucMGP levels, a biomarker of vascular calcification, and improved arterial stiffness as measured by pulse wave velocity. A separate 3-year RCT involving 244 postmenopausal women found statistically significant improvements in vertebral and femoral neck bone mineral density compared to placebo. Bioavailability studies confirm MK-7 has a plasma half-life of approximately 72 hours, far exceeding MK-4's 1-2 hour half-life, enabling once-daily dosing with sustained tissue saturation. Evidence quality is strong for biomarker endpoints but longer-term cardiovascular event reduction data in broader populations remains an area of ongoing research.

Nutritional Profile

Primary bioactive compound: Menaquinone-7 (MK-7), a long-chain form of Vitamin K2. Typical supplemental doses range from 45–180 mcg per serving (commonly standardized at 100 mcg per capsule/softgel). MenaQ7 is derived from fermentation of Bacillus subtilis natto using chickpea-based substrate, yielding all-trans MK-7 (the bioactive isomer, typically >98% all-trans configuration). Contains no significant macronutrients (negligible calories, fat, protein, carbohydrates per serving). No appreciable fiber, minerals, or other vitamins unless formulated in combination products. Key bioactive characteristics: MK-7 has a long half-life of approximately 72 hours (compared to ~1–2 hours for Vitamin K1/phylloquinone and ~6–8 hours for MK-4), enabling sustained blood levels and more complete extrahepatic carboxylation of vitamin K-dependent proteins. Bioavailability is notably higher than synthetic MK-7 due to all-trans purity; studies show approximately 2–3× greater absorption and bioactivity versus mixed cis/trans synthetic forms. Fat-soluble compound; absorption is enhanced when taken with dietary fat (approximately 2–5× increase in AUC with a fat-containing meal versus fasting). MK-7 achieves steady-state serum concentrations within approximately 2–4 weeks of daily supplementation at 100 mcg. At 45 mcg/day, activates circulating osteocalcin; at 180 mcg/day, significantly reduces levels of dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP), the inactive form associated with vascular calcification. Does not contain Vitamin K1 (phylloquinone) or MK-4 in meaningful amounts. Excipient profile varies by formulation but typically includes medium-chain triglycerides (MCT) or soybean/sunflower oil as carrier for fat-soluble delivery. Allergen note: original natto fermentation uses soy-free chickpea substrate, making MenaQ7 soy-free, though some finished products may add soy-based excipients.

Preparation & Dosage

Clinically studied dosages are not specified in the available research. MenaQ7 is standardized to contain NLT 96% and NMT 101% all-trans MK-7, available as 2000 ppm powder formulations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Calcium, Magnesium, Omega-3 fatty acids, Vitamin A

Safety & Interactions

MenaQ7 MK-7 is generally well tolerated with no serious adverse events reported in clinical trials at doses up to 360 mcg/day. The most clinically significant interaction is with vitamin K antagonist anticoagulants such as warfarin (Coumadin); MK-7 directly opposes warfarin's mechanism by restoring clotting factor carboxylation, and even doses as low as 50 mcg/day can measurably alter INR values, making concurrent use contraindicated without close medical supervision. Patients on antiplatelet agents or other anticoagulants such as rivaroxaban or apixaban should consult a physician before use, as interactions are theoretically possible. Safety data in pregnancy and lactation is insufficient to establish formal recommendations, so use during these periods should be discussed with a healthcare provider.